MR Imaging and SPECT findings in nine patients with DAVF hyperintensity on T2-Weighted MR Images
Patient | Before Treatmen Findings | After Treatment Findings | Outcome | ||||
---|---|---|---|---|---|---|---|
T2-Weighted MR Imaging | SPECT | T2-Weighted MR Imaging | SPECT | ||||
At Rest | With Acetazolamide | At Rest | With Acetazolamide | ||||
Type 2a | |||||||
12 | Hyperintensity | Hypoperfusion | Preserved | T2-normalization at 1 mo | Normal | Not done | Good |
13 | Hyperintensity | Hypoperfusion | Preserved | T2-normalization at 2 wk | Normal | Not done | Good |
14 | Hyperintensity | Hypoperfusion | Preserved | T2-normalization at 2 wk | Normal | Not done | Good |
15 | Hyperintensity | Hypoperfusion | Preserved | T2-normalization at 1 wk | Normal | Not done | Good |
16 | Hyperintensity | Hypoperfusion | Preserved | T2-normalization at 3 wk | Normal | Not done | Good |
17 | Hyperintensity | Hypoperfusion | Preserved | T2-normalization at 2 wk | Normal | Not done | Good |
18 | Hyperintensity | Hypoperfusion | Preserved | T2-normalization at 3 wk | Normal | Not done | Good |
Type 2b | |||||||
19 | Hyperintensity | Hypoperfusion | Non-preserved | T2-hyperintensity continued, subcortical hemorrhage | Hypoperfusion, peripheral hyperperfusion | Non-preserved | Poor |
20 | Hyperintensity | Hypoperfusion | Non-preserved | T2-hyperintensity continued | Hypoperfusion | Non-preserved | Poor |
21 | Hyperintensity | Hypoperfusion | Non-preserved | T2-hyperintensity continued | Hypoperfusion | Non-preserved | Poor |
22 | Hyperintensity | Hypoperfusion | Non-preserved | T2-hyperintensity continued | Hypoperfusion | Non-preserved | Poor |